Why is Concord Drugs falling/rising?

As of 23-Jul, Concord Drugs Ltd is currently priced at 57.25, reflecting a decline of 1.16, or 1.99%. The stock has been underperforming, having fallen consecutively for the last seven days, resulting in a total drop of 14.55% during this period. Despite a strong performance over the past year with a return of 47.40%, the stock's profits have decreased by 13%, indicating potential concerns about its profitability. Additionally, the stock is trading at a discount compared to its peers, which may suggest an attractive valuation, but the recent decline in investor participation, with delivery volume dropping by 41.67%, raises questions about market confidence.
In the broader market context, Concord Drugs has underperformed the Sensex in the short term, with a 9.57% decline over the past week compared to a slight increase of 0.11% in the benchmark index. While the stock has shown significant long-term performance, outperforming the BSE500 over various time frames, the recent negative trend and falling investor interest could be contributing to its current price drop. The liquidity of the stock remains adequate for trading, but the overall sentiment appears to be cautious as reflected in the recent price movements.